Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity

M. Hoffmann, L. Saleh-Ebrahim, F. Zwicker, P. Haering, A. Schwahofe, J. Debus, P.E. Huber, and F. Roeder

Abstract

Background: To report our long-term results with postoperative intensity-modulated radiation therapy (IMRT) in patients suffering from squamous-cell carcinoma (SCC) of the oral cavity or oropharynx.

Methods: Seventy five patients were retrospectively analyzed. Median age was 58 years and 84 % were male. 76 % of the primaries were located in the oropharynx. Surgery resulted in negative margins (R0) in 64 % of the patients while 36 % suffered from positive margins (R1). Postoperative stages were as follows: stage1:4 %, stage2:9 %, stage3:17 %, stage4a:69 % with positive nodes in 84 %. Perineural invasion (Pn+) and extracapsular extension (ECE) were present in 7 % and 29 %, respectively. All patients received IMRT using the step-and-shoot approach with a simultaneously integrated boost (SIB) in 84 %. Concurrent systemic therapy was applied to 53 patients, mainly cisplatin weekly.

Results: Median follow-up was 55 months (5–150). 13 patients showed locoregional failures (4 isolated local, 4 isolated neck, 5 combined) transferring into 5-year-LRC rates of 85 %. Number of positive lymph nodes (n > 2) and presence of ECE were significantly associated with decreased LRC in univariate analysis, but only the number of nodes remained significant in multivariate analysis. Overall treatment failures occurred in 20 patients (9 locoregional only, 7 distant only, 4 combined), transferring into 3-and 5-year-FFTF rates of 77 % and 75 %, respectively. The 3-and 5-year-OS rates were 80 % and 72 %, respectively. High clinical stage, high N stage, number of positive nodes (n > 2), ECE and Pn1 were significantly associated with worse FFTF and OS in univariate analysis, but only number of nodes remained significant for FFTF in multivariate analysis. Maximum acute toxicity was grade 3 in 64 % and grade 4 in 1 %, mainly hematological or mucositis/dysphagia. Maximum late toxicity was grade 3 in 23 % of the patients, mainly long-term tube feeding dependency.

Conclusion: Postoperative IMRT achieved excellent LRC and good OS with acceptable acute and low late toxicity rates. The number of positive nodes (n > 2) was a strong prognostic factor for all endpoints in univariate and the only significant factor for LRC and FFTF in multivariate analysis. Patients with feeding tubes due to postoperative complications had an increased risk for long-term feeding tube dependency.

Keywords: Oropharyngeal cancer, Postoperative, IMRT
Background
The main treatment modalities for head and neck cancer are surgery and radiation therapy [1–5]. While very early stages can be successfully treated with one of those modalities alone, surgical candidates with more advanced stages usually require the combination of both [5] to achieve satisfactory locoregional control. Further on, enhancement of radiation therapy by simultaneous application of chemotherapy has been shown to be advantageous according to randomized trials in the presence of several risk factors especially positive or close resection margins and nodal involvement with extracapsular extension (ECE) [3, 4, 6]. However, in most of these trials patients with different tumor locations have been included and treated uniformly, although tumor localization might influence treatment opportunities and outcome both regarding oncological and functional endpoints [7, 8]. For example, surgical opportunities in oral cavity and oropharyngeal tumors can be limited with regard to radicality because of unacceptable functional deficits [9], which fueled even the investigation of neoadjuvant chemoradiation approaches specifically in those cases [10]. In fact several authors reported different outcomes for oral cavity or oropharyngeal tumors compared to other head and neck sites [8, 11]. However, both surgical and radiation therapy techniques have evolved in the last decades. While the surgical approach has been improved for example by the widened use of reconstructions with microvascular free flaps [9], the introduction of intensity-modulated radiation therapy (IMRT) represents a major progress in radiation therapy. As shown by various dosimetric and clinical studies, IMRT allows improved target coverage and reduced dose to organs at risk at the same time which consequently leads to less acute and late toxicities [12, 13]. Further on, IMRT offers a simple solution to apply slightly accelerated doses in areas of high risk [14–16] like the surgical cavity without increasing the number of fractions (so-called simultaneously integrated boost concept, SIB). Taken together, little long-term data exists specifically addressing the subgroup of patients with oral cavity or oropharyngeal primaries treated with postoperative IMRT with or without chemotherapy depending on the presence of risk factors established in randomized trials using conventional techniques. We therefore retrospectively evaluated our patients treated in this setting with regard to outcome, toxicity and possible prognostic factors to gain a more specific insight into the long-term clinical behavior of this patient subgroup in the era of modern radiation techniques.

Methods
Patient characteristics
We retrospectively analyzed our patients with squamous cell cancer of the oral cavity or the oropharynx who have been treated with postoperative intensity-modulated radiation therapy after gross complete resection at our institution between 2000 and 2010. Oral cavity cancer was defined as primary tumor located in the mucosal surface of lip, floor of mouth, oral tongue, buccal mucosa, lower and upper gingival, hard palate and retromolar trigone, according to UICC6th definition. Oropharyngeal cancer was defined as primary tumor located in the soft palate, tonsil, base of tongue and lateral or posterior wall of the pharynx between soft palate and hyoid according to UICC6th definition. Patients with distant spread or locally recurrent disease at presentation, gross residual disease after resection, prior radiation therapy of the head and neck region, induction chemotherapy or non-squamous cell cancer histology were excluded. The remaining 75 patients formed the basis of the current analysis. Median age was 58 years (35–85) and 84 % were male. 61 % of the primaries were located in the oropharynx. Surgery resulted in microscopically negative margins (R0) in 64 % of the patients while 36 % suffered from positive margins (R1). All patients received ipsilateral (45 %) or bilateral neck dissections (55 %). Postoperative tumor stages (UICC6th 2002) were distributed as follows: stage 1: 3 %, stage 2:7 %, stage 3: 13 %, stage 4a: 52 % with positive lymph nodes in 84 % of the patients. Grading was G1 in 3 %, G2 in 57 % and G3 in 40 %. Perineural invasion (Pn+) was present in 7 %, extracapsular extension (ECE) in 29 %. For detailed patient characteristic see Table 1.

Work-up and surgery
Initial work-up prior to surgery included clinical and laboratory examination, computed tomography (CT) and/or magnetic resonance imaging (MRI) of the head and neck, endoscopy with histological confirmation, chest x-ray or CT and abdominal ultrasound or CT. Surgery included various techniques for gross primary tumor removal with flap reconstructions if technically needed and ipsi-or bilateral neck dissection according to the principles of head and neck cancer surgery. Indication for postoperative radiation was seen in locally advanced primary tumors (T3/4), positive lymph nodes (N+) or incomplete resection. In case of incomplete resection or positive lymph nodes with extracapsular extension, patients were scheduled for simultaneous planning-based chemotherapy if medically fit. Surgery attempted gross complete removal of the primary by various techniques and ipsi-or bilateral neck dissection. Radiation was planned to be initiated 4–8 weeks after surgery if primary wound closure was achieved.

Radiation therapy
All patients received postoperative IMRT using the step and shoot approach. The technique used in our institution has been described previously [14, 17, 18]. Briefly, all
| Table 1 Patient and Treatment characteristics |

|                          | n  | %  | Follow-up       | n  | %  |
|--------------------------|----|----|-----------------|----|----|
| **Age**                  |    |    |                 |    |    |
| median                   | 58 | 84 | median 55 mo    |    |    |
| min                      | 35 | 84 | min 5 mo        |    |    |
| max                      | 85 | 84 | max 150 mo      |    |    |
| **Gender**               |    |    | RT break > 3d   |    |    |
| male                     | 63 | 84 | yes 3          | 4  |
| female                   | 12 | 16 | no 72          | 96 |
| **Localisation**         |    |    | SIB            |    |    |
| oral cavity              | 18 | 24 | yes 63         | 84 |
| oropharynx               | 57 | 76 | no 12          | 16 |
| **pT stage**             |    |    |                 |    |    |
| pT1                      | 23 | 31 | median 9       |    |    |
| pT2                      | 36 | 48 | min 5          |    |    |
| pT3                      | 9  | 12 | max 10         |    |    |
| pT4a                     | 7  | 9  |                |    |    |
| **pN stage**             |    |    |                 |    |    |
| pN0                      | 12 | 16 | min 50 Gy      |    |    |
| pN1                      | 12 | 16 | max 60 Gy      |    |    |
| pN2a                     | 5  | 7  |                |    |    |
| pN2b                     | 39 | 52 |                |    |    |
| pN2c                     | 7  | 9  | median 66 Gy   |    |    |
| **clinical stage (UICC6)**|    |    |                 |    |    |
| stage 1                  | 3  | 4  |                |    |    |
| stage 2                  | 7  | 9  | SD nodes       |    |    |
| stage 3                  | 13 | 17 | median 1.8 Gy  |    |    |
| stage 4a                 | 52 | 69 | min 1.8 Gy     |    |    |
|                         |    |    | max 2 Gy       |    |    |
| **Grading**              |    |    |                 |    |    |
| G1                       | 2  | 3  | SD Boost       |    |    |
| G2                       | 43 | 57 | median 2.2 Gy  |    |    |
| G3                       | 30 | 40 | min 2 Gy       |    |    |
|                         |    |    | max 2.33 Gy    |    |    |
| **ECE**                  |    |    |                 |    |    |
| yes                      | 22 | 29 | Chemotherapy   |    |    |
| no                       | 53 | 71 | yes 53         | 71 |
|                         |    |    | no 22          | 29 |
| **Perineural invasion**  |    |    | CHT scheme/compl.|    |    |
| Pn0                      | 70 | 93 | Cis weekly 47  | 89 |    |
| Pn1                      | 5  | 7  | Carbo/5-FU 5   | 9  |
|                         |    |    | Cetuximab 1    | 1  |

Hoffmann et al. Radiation Oncology (2015) 10:251
patients were fixed in an individually manufactured precision head mask made of Scotch cast (3 M, St. Paul, Minneapolis, MN) and a vacuum pillow for the body. With this immobilization system attached to the stereotactic base frame, contrast-enhanced CT-images were performed with a slice thickness of at least 3 mm. Target volume definition differed slightly over time but usually the primary clinical target volume included the surgical tumor bed with a safety margin of 1 cm and the bilateral regional lymph nodes areas (retro-, parapharyngeal, cervical nodes level Ib-V). Secondary CTVs (Boost) covered the surgical tumor bed and the regions of involved lymph nodes with extracapsular extension. A PTV margin of 3–5 mm was added manually to the CTVs. Margins could be reduced in case of directly adjacent organs at risk. Inverse treatment planning was performed using the KonRad and VIRTOUS software developed at the German Cancer Research center (DKFZ). EBRT was delivered by linear accelerators with 6 or 15 MV photons using an integrated motorized multileaf collimator (MLC) in step-and shoot technique. Since the introduction of a kV-CT on rails in 2002, all patients received image guidance (with the possibility for replanning if necessary) at least once a week. The total doses were prescribed to the median of the target volume and usually the 95 % isodose surrounded the PTV. A simultaneously integrated boost concept (SIB) was used in the majority of patients (84 %). According to this concept, the boost volume (surgical bed, nodal regions with ECE) should be covered with 66 Gy (single dose 2.2 Gy) while the nodal areas should receive 54 Gy (single dose 1.8 Gy) in 30 fractions. An example of a three dimensional dose distribution including a DVH sample is shown in Fig. 1. At least one parotid gland was spared (mean dose lower than 26 Gy). In patients with sequential boost concepts, conventional fractionation was used (1.8-2 Gy). Chemotherapy schedules varied slightly over time, but in general patients were scheduled for concurrent platin-based systemic therapy in case of microscopic residual disease (R1 resection), close margin resection or if extracapsular extension was present.

**Follow-up**

Regular follow-up visits took place either at our or at the referring center. At our institution, patients were

| Table 1 Patient and Treatment characteristics (Continued) |
|---------------------------------|--------|--------|-----------------------------|--------|---------|
| n ≤ 2  | 44  | 59  | >80 % of scheduled  | 41  | 77% |
| n > 2  | 31  | 41  | <80 % of scheduled  | 12  | 23% |
| Resection margin                  | Neck dissection |
| R0                               | 48  | 64  | ipsilateral       | 34  | 45    |
| R1                               | 27  | 36  | bilateral         | 41  | 55    |

*Yrs years, min minimum, max maximum, n number, %:percentage, UICC Union International contre le cancer staging manual 6th edition, ECE extracapsular extension, pos. positive, RT radiation therapy, d days, mo months, TD total dose, SD: single dose, CHT chemotherapy, compl.completion, Cis cisplatin, Carbo carboplatin, 5-FU 5-fluorouracil, SIB simultaneously integrated boost, *percentage of 53 patients with CHT*
scheduled for follow up visits every 3 months for the first 2 years, every six months for the following 3 years and annually thereafter. Each visit included at least clinical examination and CT or MRI of the head and neck. In case of evidence for locoregional recurrence or distant spread, additional tests or imaging modalities were performed to confirm or exclude disease progression at the discretion of the treating physician. Missing data were completed by calling the patients or the treating physician.

**Definition of events**
Local control (LC) was defined as absence of tumor regrowth in the region of the primary tumor. Neck control (NC) was defined as absence of tumor regrowth in the bilateral regional nodes. Locoregional control (LRC) was defined as absence of local or neck recurrence. In patients without further assessment of LC/NC/LRC, for example after development of distant spread, the date of the last information about the local/neck/regional status was used for calculation. Distant control (DC) was defined as absence of distant failure. Freedom from treatment failure (FFTF) was defined as absence of regional or distant failure. All patients were (re-)staged according to UICC 6th edition. Postoperative complications, acute and late side effects were reported as documented in the patient charts. Acute toxicity was scored according to Common Toxicity Criteria version 3.0 (CTCAE V3.0) from the start of radiation therapy until 3 months of follow up. Late toxicity was scored according to CTCAE 3.0 thereafter until the end of follow-up. If multiple occurrence was documented, the most severe grade of a specific event was used for grading. Disease related functional impairments present prior to the start of chemoradiation were scored as toxicity only if worsening occurred. Xerostomia was scored as subjectively assessed by the patients and graded according to Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment (EORTC) radiation morbidity scoring criteria [19].

**Statistical and ethical considerations**
Time to event data was calculated from the first day of radiation treatment until the last follow up information or until death using the Kaplan-Meier method. Subgroups were compared using the log-rank test. Parameters with \( p < 0.1 \) in univariate analysis were entered into a Cox regression model for multivariate analysis. Differences were considered statistically significant for a \( p \)-value of \( \leq 0.05 \). The study is in compliance with the Declaration of Helsinki (Sixth Revision, 2008). Furthermore the study was approved by the Independent Ethics Committee of the Medical Faculty Heidelberg (Ref. Nr.: S-170/2012). All patients gave written informed consent before treatment initiation.

**Results**
The median follow up for the entire cohort was 55 months (5–150) and 62 months in survivors (12–150). Only two of the surviving patients had a follow-up interval less than 2 years. Radiation Treatment breaks >3 days were needed in 3 patients (one due to skin/mucosal toxicity, one due to suspected flap necrosis and one due to acute appendicitis). Median radiation treatment time was 43 days (36–57 days). 77 % of the patients scheduled for chemotherapy received at least 80 % of the planned chemotherapy dose.

**Locoregional control**
We observed a total of 13 locoregional failures (4 isolated local, 4 isolated neck and 5 combined), transferring into estimated 3-and 5-year locoregional control rates of 85 % (Fig. 2). The corresponding 3- and 5-year figures for local control and neck control were 90 % and 89 %. The number of positive lymph nodes \( (n > 2) \) and the presence of ECE were significantly associated with decreased locoregional and neck control in univariate analysis (Table 2, Fig. 3), but only the number of positive nodes remained significant according to multivariate analysis. Regarding local control, also postoperative T stage and presence of perineural invasion were significantly affected with worse outcome but only T stage remained significant in multivariate analysis (data not shown).

**Distant control, FFTF and OS**
Distant metastases were observed in 11 patients mainly to the lung \( (n = 8) \), transferring into estimated 3-and 5-year distant control rates of 85 % (Fig. 2). Higher postoperative T stage \( (pT3/4) \), higher N stage \( (pN2) \) and number of positive nodes \( (n > 2) \) significantly affected distant control in univariate analysis (Table 2, Fig. 3). Overall treatment failure occurred in 20 patients \( (9 \) locoregional only, 7 distant only, 4 combined), transferring into estimated 3-and 5-year FFTF rates of 77 % and 75 %, respectively (Fig. 2). The estimated 3-and 5-year overall survival rates were 80 % and 72 %, respectively (Fig. 2). Worse FFTF and OS were significantly associated with postoperative N2 stage, clinical stage 4, number of positive nodes \( (n > 2) \), presence of ECE and perineural invasion (Table 2, Fig. 3). According to multivariate analysis, only the number of positive nodes was significantly associated with worse FFTF while none of the factors remained significant regarding overall survival.

**Toxicity**
Postoperative complications were documented in 23 patients (31 %), mainly as persistent dysphagia or aspiration requiring percutaneous endoscopic gastrostomy tubes (PEG, \( n = 13, 17 \) %), see Table 3. Surgical revisions were needed in 5 patients (7 %). Maximum acute toxicity grade 3 was scored in 48 patients (64 %) mainly as leukopenia or mucositis/dysphagia and grade 4 in one
patient (leucopenia), see Table 4. This includes 25 patients scored as grade 3 dysphagia due to presence of a PEG at the initiation of radiation therapy (13 with PEGs placed due persistent dysphagia or aspiration postoperatively, 12 with PEGs placed prophylactically at the discretion of the treating physician), resulting in an overall acute grade 3 dysphagia rate of 52%. If only the 50 patients without PEG at the initiation of radiation therapy were regarded, the rate of grade 3 dysphagia would have dropped to 28%, see Table 5. Maximum late toxicity grade 3 was documented in 17 patients (23%), mainly as long term PEG dependency ($n = 11, 15\%$), see Table 6. Patients with PEGs due to postoperative complications had a markedly increased risk of long-term tube dependency (5/13, 38%) compared to patients who received PEGs for other reasons or not at all during radiation therapy (6/62, 10%), see Table 5.

**Discussion**

In our current analysis of 75 patients suffering from oral cavity or oropharyngeal squamous cell carcinoma, we show that encouraging locoregional control rates (5-year LRC 85%) and overall survival rates (5-year OS 72%) can be achieved with postoperative IMRT with or without simultaneously applied chemotherapy according to the presence of established risk factors with acceptable acute and limited late toxicities. Despite the general limitations in comparing different studies, our results seem to compare favourable with the findings of large prospective trials using similar approaches with conventional radiation techniques in head and neck cancer especially with regard to overall survival [3, 4]. For example, Bernier et al. [4] reported a 5-year local or regional recurrence rate of 18% and a 5-year overall survival rate of 53% in the chemoradiation arm of EORTC 22931 using a slightly different dose concept combined with cisplatin. Cooper et al. [3] described a 10-year local or regional recurrence rate of 22% and an estimated 5-year overall survival of 46% in the chemoradiation arm of RTOG 9501 which was similarly designed to EORTC 22931. Although the majority of patients in these studies suffered from oral cavity or oropharyngeal cancers (56-72%), hypopharyngeal and laryngeal cancers were also included which might have affected the overall results. Further on, the use of IMRT in the present study instead of conventional radiation might have led to an improved overall survival due to decreased late toxicities, but given the retrospective nature and the small sample size of our study, it cannot be ruled out that these differences occurred simply by selection bias or randomly. However, our results are also in good accordance with other studies focusing on IMRT and/or oral cavity and oropharyngeal cancer using modern radiation techniques. For example, Chen et al. [20] analyzed 90 consecutive head and neck

![Graphs](image-url)
### Table 2: Univariate analysis of prognostic factors

|                      | LRC 5-yr rate | p value | DC 5-yr rate | p value | FFTF 5-yr rate | p value | OS 5-yr rate | p value |
|----------------------|---------------|---------|--------------|---------|----------------|---------|--------------|---------|
| **Age**              |               |         |              |         |                |         |              |         |
| <58 yrs              | 81 %          | 0.144   | 80 %         | 0.803   | 71 %           | 0.349   | 71 %         | 0.932   |
| ≥58 yrs              | 89 %          |         | 86 %         |         | 79 %           |         | 72 %         |         |
| **Gender**           |               |         |              |         |                |         |              |         |
| male                 | 86 %          | 0.598   | 81 %         | 0.439   | 73 %           | 0.745   | 70 %         | 0.503   |
| female               | 83 %          |         | 91 %         |         | 83 %           |         | 81 %         |         |
| **Localisation**     |               |         |              |         |                |         |              |         |
| oral cavity          | 78 %          | 0.623   | 80 %         | 0.246   | 72 %           | 0.956   | 77 %         | 0.503   |
| oropharynx           | 87 %          |         | 92 %         |         | 76 %           |         | 70 %         |         |
| **Grading**          |               |         |              |         |                |         |              |         |
| G1                   | 100 %         | 0.781   | 100 %        | 0.48    | 100 %          | 0.485   | 100 %        | 0.21    |
| G2                   | 84 %          |         | 86 %         |         | 76 %           |         | 77 %         |         |
| G3                   | 87 %          |         | 77 %         |         | 72 %           |         | 62 %         |         |
| **pT stage**         |               |         |              |         |                |         |              |         |
| pT1/2                | 88 %          | 0.169   | 87 %         | 0.035   | 78 %           | 0.155   | 75 %         | 0.374   |
| pT3/4                | 74 %          |         | 66 %         |         | 63 %           |         | 59 %         |         |
| **pN stage**         |               |         |              |         |                |         |              |         |
| pN0/1                | 96 %          | 0.167   | 96 %         | 0.05    | 96 %           | 0.017   | 88 %         | 0.006   |
| pN2                  | 80 %          |         | 76 %         |         | 65 %           |         | 63 %         |         |
| **Clinical stage (UICC6th)** |   |         |              |         |                |         |              |         |
| stage 1/2/3          | 96 %          | 0.194   | 95 %         | 0.06    | 96 %           | 0.023   | 88 %         | 0.009   |
| stage 4a             | 81 %          |         | 76 %         |         | 64 %           |         | 64 %         |         |
| **Neck dissection**  |               |         |              |         |                |         |              |         |
| ipsilateral          | 91 %          | 0.318   | 90 %         | 0.13    | 81 %           | 0.311   | 85 %         | 0.082   |
| bilateral            | 80 %          |         | 76 %         |         | 69 %           |         | 59 %         |         |
| **Number of pos. nodes** |     |         |              |         |                |         |              |         |
| ≤2                   | 98 %          | 0.001   | 93 %         | 0.005   | 93 %           | 0.001   | 84 %         | 0.001   |
| >2                   | 67 %          |         | 65 %         |         | 49 %           |         | 53 %         |         |
| **Perineural invasion** |         |         |              |         |                |         |              |         |
| no                   | 87 %          | 0.092   | 83 %         | 0.452   | 77 %           | 0.016   | 74 %         | 0.044   |
| yes                  | 60 %          |         | 80 %         |         | 40 %           |         | 30 %         |         |
| **Resection margin** |               |         |              |         |                |         |              |         |
| R0                   | 81 %          | 0.725   | 86 %         | 0.609   | 75 %           | 0.745   | 67 %         | 0.499   |
| R1                   | 93 %          |         | 78 %         |         | 75 %           |         | 80 %         |         |
| **ECE**              |               |         |              |         |                |         |              |         |
| no                   | 94 %          | 0.002   | 85 %         | 0.309   | 85 %           | 0.005   | 79 %         | 0.003   |
| yes                  | 64 %          |         | 73 %         |         | 52 %           |         | 53 %         |         |
| **CHT**              |               |         |              |         |                |         |              |         |
| yes                  | 83 %          | 0.373   | 79 %         | 0.335   | 70 %           | 0.179   | 69 %         | 0.134   |
| no                   | 90 %          |         | 90 %         |         | 86 %           |         | 80 %         |         |
cancer patients treated with surgery, postoperative IMRT +/− chemotherapy and found a 2-year locoregional control rate of 80 % and a 2-year overall survival rate of 79 %. Collan et al. [5] reported a cohort of 102 patients with a stage distribution similar to ours treated by postoperative IMRT up to a median dose of 60 Gy with 38 % of them receiving simultaneous chemotherapy. With a median follow-up of 55 months, they observed very high 5-year LRC and OS rates of ~90 % (estimated from printed curve) and 84 %, respectively. Wang et al. [11] analyzed 88 patients with primaries located in oral cavity or oropharynx of whom 44 received postoperative IMRT up to 66 Gy (SD 2.2 Gy) mainly without chemotherapy with a slightly more favourable stage distribution. After a median follow-up of 53 months, they found estimated 4-year LRC control and OS rates of 84 % and 71 %, respectively. In summary, postoperative IMRT with/without chemotherapy seems to result in encouraging LRC and OS rates in patients with oral cavity or oropharyngeal cancers based on our results and the limited available literature.

Prognostic factors

Despite the relatively small sample size, we used univariate and multivariate analyses to investigate possible prognostic factors specifically for oral cavity and oropharyngeal cancer cases. Regarding locoregional control, we found that presence of ECE and number of positive nodes (n > 2) were associated with worse outcome in univariate analysis, but only the number of positive nodes remained significant according to multivariate Cox regression. Regarding FFTF and OS, worse outcome was associated with N2 stage, clinical stage 4 disease, number of positives nodes, presence of ECE and perineural invasion in univariate analysis, but again only the number of positive nodes remained significant according to multivariate analysis at least for FFTF. These findings were surprising at least to
some extent as microscopic incomplete resection and presence of ECE have been reported as strongest factors influencing locoregional control and overall survival according to major prospective trials [3, 4, 6], while the number of positive nodes is a less established factor. For example, the combined analysis of EORTC 22931 and RTOG 9501 (which stratified patients according to slightly different risk factors) observed a significant benefit for adding chemotherapy to postoperative radiation only for the common factors (positive margin and ECE), while the presence of risk factors which have been used for risk assessment only in one of the trials (number of positive nodes ≥ 2, level 4/5 involvement, vascular embolisms, perineural disease, stage III/IV) had a weaker or no prognostic

### Table 3 Postoperative complications

| Postoperative complications                  | Number | Percent |
|---------------------------------------------|--------|---------|
| Local                                       |        |         |
| Dysphagia requiring feeding tube            | 13     | 17      |
| Bleeding                                    | 4      | 5       |
| Wound healing disturbance/flap necrosis     | 3      | 4       |
| Horner's syndrome                           | 1      | 1       |
| Systemic                                    |        |         |
| MI                                          | 4      | 5       |
| DVT                                         | 2      | 3       |
| Pulmonary embolism                          | 1      | 1       |
| Tachyarrhythmia                            | 1      | 1       |
| Hypertensive crisis                         | 1      | 1       |
| Pseudomembranous colitis                    | 1      | 1       |
| Pneumonia                                   | 1      | 1       |
| Delirium                                    | 1      | 1       |
| Surgical revisions                          | 5      | 7       |

* n: number, %: percentage, MI: myocardial infarction, DVT: deep vein thrombosis, some patients had more than one postoperative complication

### Table 4 Acute toxicities

| Acute toxicities | All grades | Grade 3/4 |
|------------------|------------|-----------|
|                  | n | % | n | % |
| Non-hematological |   |   |   |   |
| Dysphagia         | 68 | 91 | 39 | 52 |
| Mucositis/stomatitis | 61 | 81 | 8 | 11 |
| Weight loss       | 32 | 43 | 5 | 7 |
| Skin              | 64 | 85 | 3 | 4 |
| Nausea/vomiting   | 29 | 39 | 3 | 4 |
| Horseiness/larynx edema | 9 | 12 | 1 | 1 |
| Hearing loss      | 9 | 12 | 1 | 1 |
| Renal injury      | 7 | 9 |   |   |
| Dry eye           | 1 | 1 |   |   |
| Hand foot syndrome | 1 | 1 |   |   |
| Other             | 3 | 4 | 2 | 3 |
| Hematological     |   |   |   |   |
| Leucopenia        | 39 | 52 | 8 | 10 |
| Infection         | 16 | 21 | 5 | 7 |
| Anemia            | 51 | 68 | 4 | 5 |
| Thrombocytopenia  | 18 | 24 |   |   |

*: only one patient had a grade 4 toxicity (leucopenia), a: all patients included with PEGs regardless of its reason or use, some patients had more than one acute toxicity

### Table 5 Acute and late dysphagia in relation to PEG placement

| Dysphagia | All patients | Without PEG at start of RT |
|-----------|--------------|----------------------------|
| Grade 0   | 7 | 9 | 7 | 14 |
| Grade 1   | 22 | 29 | 22 | 44 |
| Grade 2   | 7 | 9 | 7 | 14 |
| Grade 3   | 39 | 52 | 14 | 28 |

PEG: percutaneous endoscopic gastrostomy tube, RT: radiation therapy, a: all patients with PEG during RT regardless of reason for placement or use scored as grade 3 dysphagia, b: patients who received PEG postoperatively due to aspiration or persistent dysphagia until initiation of RT, c: patient who received PEG for prophylactic reasons prior to initiation of RT on discretion of the treating radiation oncologist, d: patients who received PEG during RT due to dysphagia, e: patients who did not receive a PEG during the whole course of RT, f: patients who needed PEG due to development of late dysphagia after completion of the full RT course

### Table 6 Late toxicities

| Late toxicities | All grades | Grade 3 |
|-----------------|------------|---------|
|                 | n | % | n | % |
| Dysphagia       | 28 | 37 | 11 | 15 |
| Hearing loss    | 9 | 12 | 3 | 4 |
| Xerostomia      | 38 | 51 | 2 | 3 |
| Hoarseness/laryngeal edema | 7 | 9 | 2 | 3 |
| Abscess/fistula | 2 | 3 | 2 | 3 |
| Trismus         | 8 | 11 | 1 | 1 |
| Osteonecrosis   | 1 | 1 | 1 | 1 |
| Taste alteration | 16 | 21 |   |   |
| Lymph edema     | 8 | 11 |   |   |
| Mucosal damage  | 4 | 5 |   |   |
| Hypothyreosis   | 3 | 4 |   |   |
| Dental damage   | 2 | 3 |   |   |
| Skin damage     | 1 | 1 |   |   |
| Esophageal stenosis | 1 | 1 |   |   |

*: only grade 1 and 2 possible according to CTCAE3.0, some patients had more than one late toxicity
value at all [6]. However, our patients received chemotherapy based on the presence of the established risk factors close/positive margins or ECE, thus it cannot be ruled out that the addition of chemotherapy improved the results in those patients to a level comparable to patients at lower risk receiving postoperative RT alone and therefore mimicked their prognostic relevance with regard to the entire cohort. In contrast, the number of positive nodes did not trigger the use of additional chemotherapy, possibly maintaining its influence as highlighted by several reports supporting the significance of the number of positive nodes or the lymph node ratio as prognostic factors in head and neck cancer [21, 22]. For example Hua et al. [21] described a highly significant association between number of positive nodes (threshold ≤ 3 vs > 3) and lymph node ratio with the median overall survival in 81 patients suffering from hypopharyngeal cancer treated by surgery only. Wan et al. [22] evaluated 1510 patients with head and neck cancer treated by surgery alone, adjuvant radiation or adjuvant chemoradiation and found a strong and significant association between the number of positive nodes and locoregional control, disease specific survival and overall survival. In a subset analysis, they further described no significant difference in DSS or OS between patients with one or two positive nodes but significant worsening if three or more nodes were involved. Similarly, we found that the number of positive nodes was the only factor which significantly influenced all oncological endpoints in univariate analysis and the only factor which influenced LRC and FFTF in multivariate analysis. Interestingly the strongest discrimination in our cohort was found for the same threshold (≤2 vs > 2) as in the study by Wan et al. [22]. We performed a separate analysis using the threshold introduced by Cooper et al. (<2 vs ≥ 2) [3], which provided similar results in univariate and multivariate analysis with regard to significance but with weaker discrimination (data not shown). Given the different thresholds reported in the mentioned studies with similar results, it seems at least reasonable to assume, that locoregional control and overall survival will worsen with an increasing number of positive nodes irrespective of arbitrarily set distinctions.

Toxicity
We observed maximum acute grade 3 toxicities in about two thirds of our patients, mainly hematological and mucositis/dysphagia. These findings are in line with the reports of other studies investigating postoperative radio (chemo) therapy in head and neck cancer. For example Cooper et al. [3] found maximum acute grade 3/4 toxicities in 34 % of the patients treated by postoperative radiation alone and 77 % if chemoradiation was used. Geretschläger et al. [23] described 66 % acute grade 3 side effects in their cohort of patients with oral cavity cancer treated by postoperative IMRT. Regarding only hematological side effects, 30 % grade 3 and 8 % grade 4 hematological toxicities were found in the chemoradiation arm of RTOG 9501 [3] and 16 % severe leucopenia was reported in the chemoradiation arm of the EORTC 22931 study [4], indicating that those toxicities are mainly driven by the (similar) chemotherapy component and not influenced by radiation technique or disease site relevantly.

The combined rate of severe acute mucositis/dysphagia was also similar with roughly 60 % in our study compared to 66 % in the chemoradiation arm of RTOG 9501 [3] and 51 % in the EORTC 22931 study [4], however we found a different distribution. While in those trials more patients had severe mucositis than dysphagia, we observed an opposite ratio. This might be due to the fact that our analysis was limited to oral cavity and oropharyngeal cancer resulting in the inclusion of swallowing structures into the high dose boost areas in most patients, however it seems also linked to the definition and grading of dysphagia. In our analysis, all patients who had a feeding tube at any time during radiotherapy were scored at least as grade 3 dysphagia, although many of them received their PEGs already due to postoperative complications or prophylactically prior to RT. If only those patients were considered without PEGs at the beginning of RT, the severe dysphagia rate would have dropped to 28 %, similarly to the 25 % in the chemoradiation arm of RTOG 9501 [3]. Interestingly, we found a clearly increased risk of long-term PEG dependency in patients who had PEG placement due to postoperative complications compared to placement for other reasons or not at all. The use of feeding tubes for nutritional support is a common but heavily discussed issue in head and neck radiation therapy. It has been estimated that 50-70 % of patients require a feeding tube during definitive chemoradiation, 15-40 % with definitive RT and 20-40 % with surgery followed by adjuvant RT [24]. Many investigators favor the prophylactic use of feeding tubes because of numerous reports describing less weight loss, improved 6-month quality of life, less morbidity and fewer hospitalizations including one randomized trial supporting this approach [25–27]. However, an increasing number of reports described high percentages of unnecessary (unused) prophylactic feeding tube placements of up to 50 % [28], a higher likelihood of prolonged or permanent dependency [29] and an increased rate of esophageal strictures [30], thus favoring a more reactive approach. Unfortunately most reports focused on patients with definitive radio (chemo) therapy resulting in very limited data for patients treated with postoperative radiation [31]. Collan et al. [5] described 5 % patients with long term PEG dependency but did not report details about reasons for placement. Bastos de Souza et al. [9] found 8 % long term dependency in a cohort of 256 patients treated by surgery alone or surgery plus radiotherapy. We did not observe a

Page 10 of 13
Hoffmann et al. Radiation Oncology (2015) 10:251
major difference in prolonged PEG dependency between patients with prophylactic (17 %), symptomatic (0 %) or no placement (9 %) during radiotherapy and therefore are not able to add evidence to this issue, however we found that patients with postoperative swallowing complications requiring tube feeding are at increased risk (39 %) for prolonged PEG-dependency after postoperative radiotherapy. Thus the data may add valuable information to the limited body of evidence specifically addressing this subgroup of patients.

In contrast to other reports focusing on postoperative IMRT in oropharyngeal/oral cavity cancer most of our patients were treated with a simultaneously integrated boost (SIB) concept using slightly increased single doses (up to 2.2 Gy) in the boost area. SIB techniques allow a slightly reduced overall treatment time and result in increased dose conformity regarding the boost area but have been associated with concerns regarding additional toxicity. Although inter-study comparisons are generally difficult and possibly flawed with several biases including patient selection or the use of different scoring systems, we did not observe markedly increased rates of acute or late toxicities compared to reports on sequential IMRT boost techniques [5, 23]. This is especially true for damage to mucosal or swallowing structures, which are regarded as possibly associated with increased single doses. However, our acute grade 3 toxicity rates of 11 % for mucositis and 28 % for dysphagia (in patients without prophylactic PEG placement) were at least comparable to Collan et al. (mucositis grade 3: 25 %) [5] and Geretschläger et al. (mucositis grade 3: 36 %, dysphagia grade 3: 34 %) [23] using strictly sequential boosts. Regarding late dysphagia, our rate of 15 % was slightly increased compared to 5-9 % in the mentioned reports [5, 23], however Collan et al. [5] treated their patients with a considerably lower median total dose compared to our study and Geretschläger et al. [23] included only patients with oral cavity tumors probably resulting in lower doses to the swallowing structures. Gupta et al. [12] recently used an integrated boost concept very similar to ours in a prospective phase randomized trial and reported very low rates of grade 3 mucositis (6 %) and dysphagia (10 %). Finally, Spiotto et al. compared IMRT using sequential and integrated boost concepts in advanced head and neck cancers and reported significantly reduced acute grade 3 mucositis for the integrated boost group [34]. In summary, the use of an integrated boost technique with slightly increased single doses does not seem to result in markedly increased toxicities compared to sequential boosting techniques.

Obviously our study has some limitations, mainly its retrospective nature and its limited number of patients. Nevertheless, it describes a homogenous cohort of consecutive patients with oral cavity or oropharyngeal cancer treated uniformly with postoperative IMRT with or without chemotherapy. Thus the data may add valuable information to the limited body of evidence specifically addressing this subgroup of patients.

Conclusion

In summary, postoperative IMRT with or without chemotherapy achieves excellent locoregional control and good overall survival with acceptable acute and low late toxicity rates. Patients who needed PEG placement due to postoperative complications were at higher risk for prolonged PEG dependency than patients with prophylactic, symptomatic or no PEG placement during radiotherapy. While the selective addition of chemotherapy may have compensated the influence of established risk factors like positive margins or extracapsular extension, the number of positive lymph nodes ($n > 2$) remained a strong prognostic factor for all endpoints including locoregional control and freedom from treatment failure.

Abbreviations

CHT: chemotherapy; CT: computed tomography; CTCAE: common toxicity criteria adverse events; CTV: clinical target volume; DC: distant control; DSS: disease specific survival; DVH: dose volume histogram; DVT: deep vein thrombosis; EBRT: external beam radiotherapy; ECE: extracapsular extension; EORTC: European organisation for research and treatment of cancer; FFTF: freedom from treatment failure; Gy: gray; IMRT: intensity-modulated radiation therapy; kV-CT: kilovoltage computed tomography; L.C: local control; LRC: locoregional control; MI: myocardial infarction; MLC: multi leaf collimator; MRI: magnetic resonance imaging; NC: neck control; OS: overall survival; PEG: percutaneous endoscopic gastrostomy tube; PTV: planning target volume; RT: radiation therapy; RTOG: radiation therapy oncology group; SGC: squamous cell carcinoma; SD: single dose; SIB: simultaneously-integrated boost; TD: total dose; UICC: Union international contre le cancer.

Competing interests

The authors declare that they have no competing interests.
Authors’ contributions
MH performed data acquisition, statistical analysis and participated in drafting the manuscript. LSE, FZ participated in radiotherapy of patients, clinical data acquisition, statistical analysis and drafting the manuscript. PH, AS participated in data acquisition (radiation physics), statistical analysis and drafting of the manuscript. JD and PEH were involved in patient radiotherapy, data analysis and revised the manuscript critically. FR participated in patient radiotherapy, data acquisition, statistical analysis, critically reviewed the data and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
None.

Author details
1Clinical Cooperation Unit Molecular Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2Department of Radiation Oncology, University Hospital of Munich (LMU), Marchioninistr. 15, 81377 Munich, Germany. 3Department of Radiation Physics, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. 5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 6National Cancer Institute of Canada, Clinical Trials Branch, Ottawa, Canada.

Received: 19 October 2015 Accepted: 27 November 2015

Published online: 04 December 2015

References
1. Chen CC, Lin JC, Chen KW. Lymph node ratio as a prognostic factor in head and neck cancer patients. Radiat Oncol. 2015;10:181.
2. De Felice F, Musio D, Terenz V, Valentini V, Cassoni A, Tombolini M, et al. Treatment improvement and better patient care: which is the most important one in oral cavity cancer? Radiat Oncol. 2014;9:263.
3. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.
4. Fernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative radiotherapy with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.
5. Collan J, Lundberg S, Avavaiva L, Back L, Kajanti M, Malikke A, et al. Patterns of relapse following surgery and postoperative intensity-modulated radiotherapy for oral and oropharyngeal cancer. Acta Oncol. 2011;50:1119–25.
6. Berlman J, Cooper JS, Pajak TF, Van Glabbeke M, Boursis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC. (22931) and RTOG (9501). Head Neck. 2005;27:34–50.
7. Studer G, Brown M, Bredell M, Graft KW, Huber G, Unnemier C, et al. Follow up after IMRT in oral cavity cancer patients. Radiat Oncol. 2012;7:84.
8. Daly ME, Le GT, Maxim PG, Loo BW, Kaplan MJ, Fischbein NJ, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010;76:1339–46.
9. Bastos de Souza TR, Pinto CA, Da Cunha Mercante AM, Nishimoto IN, Brasilino de Carvalho M, Kowalski LP. Long-term results of surgical treatment for advanced oropharyngeal squamous cell carcinoma. Head Neck. 2014;36:1146–54.
10. Freier K, Engel M, Lindel K, Flichtenmacher C, Mühling J, Hassfeld S, et al. Neoadjuvant concurrent radiochemotherapy followed by surgery in advanced oral squamous cell carcinoma (OSCC): a retrospective analysis of 207 patients. Oral Oncol. 2008;44:116–23.
11. Wang ZH, Yan C, Zhang CP, Hu HS, Tu WY, Kwan J, et al. Outcomes and xerostomia after postoperative radiotherapy for oral and oropharyngeal carcinoma. Head Neck. 2014;36:1467–73.
12. Gupta T, Agarwal J, Jain S, Phrulatpam R, Kannan S, Ghosh-Laskar S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity-modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol. 2012;104:343–8.
13. Nutting CM, Morden JP, Harrington KU, Uriuio TBG, Bhide SA, Clark C, et al. Parotid-sparing intensity-modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–36.
14. Saleh-Ebrahimi L, Zwickler F, Muenten MW, Bischof M, Lindel K, Debus J, et al. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer—a retrospective single center analysis. Radiat Oncol. 2013;8:20.
15. Roeder F, Ullrich A, Habi G, Uhl M, Saleh-Ebrahimi L, Huber PE, et al. Clinical phase II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis. BMC. Cancer. 2014;14:617.
16. Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askolylakis V, Bostel T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol. 2014;9:191.
17. Schlegel W, Kreschauke P. Inverse radiotherapy planning. Strahlenther Onkol. 1999;175:197–207.
18. Münster MW, Thillmann C, Hof H, Dingder B, Rhein B, Nill S, et al. Stereotactic intensity-modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol. 2003;66:313–21.
19. Cox JD, Steez J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:341–6.
20. Chen AM, Farwell DG, Luu Q, Chen LM, Vijayakumar S, Purdy JA. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2011;80:1423–9.
21. Hua YH, Hu QY, Piao YF, Tang Q, Fu ZF. Effect of number and ratio of positive lymph nodes in hypopharyngeal head cancer. Head Neck. 2014;37:111–6.
22. Wan XC, Egloff AM, Johnson J. Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): Who would benefit from chemoradiation after surgery? Laryngoscope. 2012;122:2712–22.
23. Greenslager A, Boj bashu B, Crowe S, Arnold A, Manser P, Haller man W, et al. Outcome and patterns of failure after postoperative intensity-modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. Radiol Oncol. 2012;7:175.
24. Verma V, Liu J, Eschen L, Daniele J, Spencer C, Lewis JS, et al. Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients. Radiat. Oncol. 2015;10:8.
25. Weggengaard RG, Flierman L, Goosens A, Brand R, Verschuur HP, Croll GA, et al. Prophylactic gastrostomy placement and early tube feeding may limit loss of weight during chemoradiotherapy for advanced head and neck cancer, a preliminary study. Clin Otolaryngol. 2007;32:384–90.
26. Slander E, Nymann J, Bove M, Johansson L, Larsson S, Hammad M. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck. 2012;34:1–9.
27. Cady J. Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs. 2007;11:875–80.
28. Madhoun MF, Blankenship MM, Blankenship DM, Krempa GA, Tierney WM. Prophylactic PEG placement in head and neck cancer: how many feeding tubes are unused (and unnecessary)? World J Gastroenterol. 2011;17:1004–8.
29. Mclaughlin BT, Gokhale AS, Shuai Y, Diacopulos J, Carrau R, Heron DE, et al. Prophylactic PEG placement and early tube feeding may limit loss of weight during chemoradiotherapy for advanced head and neck cancer, a preliminary study. Clin Otolaryngol. 2007;32:384–90.
30. Slander E, Nymann J, Bove M, Johansson L, Larsson S, Hammad M. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck. 2012;34:1–9.
31. Cady J. Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs. 2007;11:875–80.
32. Madhoun MF, Blankenship MM, Blankenship DM, Krempa GA, Tierney WM. Prophylactic PEG placement in head and neck cancer: how many feeding tubes are unused (and unnecessary)? World J Gastroenterol. 2011;17:1004–8.
33. Münter MW, Hoffner S, Hof H, Herfarth KK, Haberkorn U, Rudat V, et al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. Int J Radiat Oncol Biol Phys. 2007;67:651–9.

34. Spiotto M, Weichselbaum RR. Comparison of 3D conformal radiotherapy and intensity-modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancers. Plos one. 2014;9, e94456.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit